drugset / Trial / NCT02036255

Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase

NCT02036255

Phase 3 Completed 68 enrolled University Hospital Brussels
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of our study is to investigate whether the substitution of the standard locking solution with a locking solution containing taurolidine and urokinase weekly (Taurolock ™ U 25,000 - www.taurolock.com ) reduces the rate of catheter dysfunction in hemodialysis patients with a history of TCC dysfunction requiring urokinase therapy.

Timeline

Start
2015-05
Primary completion
2017-07
Completion
2018-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Heparin Other / unclassified 500 iu Other
Subject Urokinase Protein / enzyme biologic 25000 unknown Other
Background taurolidine Small molecule Other

Indications